Case Report

Methimazole-induced Cholestatic Jaundice

Authors: Nasser E. Mikhail, MD, MSC

Abstract

Methimazole is a widely used and generally well-tolerated antithyroid agent. A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism. The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications. When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole. In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice. Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Stanley MM, Astwood EB. 1-methyl-2-mercaptoimidazole: An antithyroid compound highly active in man. Endocrinology 1949; 44: 588–589.
 
2. Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 1981; 6: 401–428.
 
3. Cooper DS. Treatment of thyrotoxicosis, in Braveman LE, Utiger RD (eds): Werner and Ingbars The Thyroid. Philadelphia, Lippincott-Raven, 1996, ed 7, pp 713–734.
 
4. Specht NW, Boehme EJ. Death due to agranulocytosis induced by methimazole therapy. JAMA 1952; 149: 1010–1011.
 
5. Rosenbaum H, Reveno WS. Agranulocytosis and toxic hepatitis from methimazole. JAMA 1953; 152: 27.
 
6. Shipp J. Jaundice during methimazole (Tapazole) administration. Ann Intern Med 1955; 42: 701–706.
 
7. Tennenbaum JI, Dreskin H. Toxic hepatitis during treatment with methimazole (Tapazole): Report of a case with apparent recovery. Ohio State Med J 1962; 58: 306–307.
 
8. Martinez-Lopez JI, Greenberg SE, Kling R. Drug-induced hepatic injury during methimazole therapy. Gastroenterology 1962; 43: 84–87.
 
9. Becker CF, Gorden P, Robbins J. Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. JAMA 1968; 206: 1787–1789.
 
10. Fisher MG, Nayer HR, Miller A. Methimazole-induced jaundice. JAMA 1973; 223: 1028–PubMed | CrossRef
 
11. Jansen PL, Froeling PG, Schade RW, et al. Intrahepatic cholestasis in hyperthyroidism and the effect of antithyroid and β-blocking drugs. Neth J Med 1982; 25: 318–324.
 
12. Schmidt G, Borsch G, Muller KM, et al. Methimazole-associated liver injury: Case report and brief literature review. Hepatogastroenterology 1986; 33: 244–246.
 
13. Arab D, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80: 1083–1085.
 
14. Schwab GP, Wetscher GJ, Vogl W, et al. Methimazole-induced liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chir 1996; 381: 225–227.
 
15. Prost G, Dechavanne M, Levenq P, et al. Cholestatic jaundice caused by carbimazole [in French]. Nouv Presse Med 1973; 2: 2479(letter).
 
16. Dinsmore WW, O’Hara MD, Callender ME. Postanesthetic carbimazole jaundice. N Engl J Med 1983; 309: 438(letter).
 
17. Blom H, Stolk J, Schreuder HB, et al. A case of carbimazole-induced intrahepatic cholestasis. An immune-mediated reaction? Arch Intern Med 1985; 145: 1513–1515.
 
18. Ayensa C, Diaz De Otazo R, Cia JM. Carbimazole-induced cholestatic hepatitis. Arch Intern Med 1986; 146: 1455(letter).
 
19. Epeirier JM, Pageaux GP, Coste V, et al. Fulminant hepatitis after carbimazole and propranolol administration. Eur J Gastroenterol Hepatol 1996; 8: 287–288.
 
20. Cales P, Voigt JJ, Suduca JM, et al. Cholestatic jaundice caused by carbimazole [in French]. Presse Med 1987; 16: 1005.
 
21. Ozenne G, Manchon ND, Doucet J, et al. Carbimazole-induced cholestatic jaundice. J Clin Gastroenterol 1989; 11: 95–97.
 
22. Sadoul JL, Canivet B, Freychet P. Toxic hepatitis induced by antithyroid drugs: Four cases including one with cross-reactivity between carbimazole and benzylthiouracil. Eur J Med 1993; 2: 473–477.
 
23. Kang H, Choi JD, Jung IG, et al. A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. Korean J Intern Med 1990; 5: 69–73.
 
24. Baker B, Shapiro B, Fig LM, et al. Unusual complications of antithyroid drug therapy: Four case reports and review of literature. Thyroidology 1989; 1: 17–26.
 
25. Lunzer M, Huang S, Ginsburg J, et al. Jaundice due to carbimazole. Gut 1975; 16: 913–917.
 
26. Yao JD, Gross JB Jr, Ludwig J, et al. Cholestatic jaundice in hyperthyroidism. Am J Med 1989; 86: 619–620.
 
27. Lersch C, Seige M, Natrath W, et al. Cholestasis induced by hyperthyroidism after liver transplantation. Digestion 1995; 56: 429–432.
 
28. Babini G, Gurioli L, Rizzi R, et al. Appearance of severe jaundice after radiometabolic treatment of thyrotoxicosis. J Endocrinol Invest 1999; 22: 209–211.
 
29. Anton Aranda A. Intrahepatic cholestasis in untreated hyperthyroidism [in Spanish]. Rev Esp Enferm Dig 2000; 92: 49–50.
 
30. Scanlon MF, Toft AD. Regulation of thyrotropin secretion, in Braveman LE, Utiger RD (eds): Werner and Ingbars The Thyroid. Philadelphia, Lippincott-Raven, 1996, ed 7, pp 220–240.
 
31. Ozenirler S, Tuncer C, Boztepe U, et al. Propylthiouracil-induced hepatic damage. Ann Pharmacother 1996; 30: 960–963.
 
32. Eisen MJ. Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 1953; 249: 814–816.
 
33. Maggiore G, Larizza D, Lorini R, et al. Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr 1989; 8: 547–548.
 
34. Cooper DS, Bodes HH, Nath B, et al. Methimazole pharmacology in man: Studies using a newly developed radioimmunoassay for methimazole. J Clin Endocrinol Metab 1984; 58: 473–479.
 
35. Methimazole, in Murray L (ed): Product Drug Reference. Montvale, NJ, Medical Economics Co., 2002, ed 56, pp 1823–1824.
 
36. Huang M, Li K, Wei JS, et al. Sequential liver and bone biochemical changes in hyperthyroidism: Prospective controlled follow-up study. Am J Gastroenterol 1994; 89: 1071–1076.